Can we safely use systemic treatment in atopic dermatitis during the COVID-19 pandemic? Overview of selected conventional and biologic systemic therapies

References

• Torres T, Puig L. Managing cutaneous Immune-Mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol. 2020;21(3):307–311.
   PubMed Web of Science ®Google Scholar
• ECDPC. European center for disease prevention and control. Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – seventh update. Eur Cent Dis Prev Control. 2020;2019:31.
   Google Scholar
• World Health Organization. [cited 2020 Nov 10]. Available from: www.who.int
   Google Scholar
• Patruno C, Stingeni L, Fabbrocini G, et al. Dupilumab and COVID-19: what should we expect?. Dermatol Ther. 2020;18–20. DOI:10.1111/dth.13502..
   Web of Science ®Google Scholar
• Mizumoto K, Chowell G. Estimating risk for death from coronavirus disease, China, January-February 2020. Emerg Infect Dis. 2020;26(6):1251–1256.
   PubMed Web of Science ®Google Scholar
• Feng Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380–1388.
   PubMed Web of Science ®Google Scholar
• Hu B, Huang S, Yin L. The cytokine storm and COVID‐19. J Med Virol. 2020;2:0–2.
   Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
   PubMed Web of Science ®Google Scholar
• Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020 May 19;52(5):731–733.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.
   PubMed Web of Science ®Google Scholar
• Buhl T, Beissert S, Gaffal E, et al. COVID-19 and implications for dermatological and allergological diseases. 2020;1–10. J Ger Soc Dermatology. DOI:10.1111/ddg.14195.
   Google Scholar
• Shelley K, Uppal BS, Donovan G. et al. Management of atopic dermatitis during the COVID-19 pandemic. Practical Dermatology. 2020; 48–64.
   Google Scholar
• Rantala A, Jaakkola JJK, Jaakkola MS. Respiratory infections in adults with atopic disease and IgE antibodies to common aeroallergens. PLoS One. 2013;8(7):1–7.
   Web of Science ®Google Scholar
• Gerbens LAA, Hamann SAS, Brouwer MWD, et al. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. Br J Dermatol. 2018;178(6):1288–1296.
   PubMed Web of Science ®Google Scholar
• Ariens LFM, Gadkari A, Van Os-Medendorp H, et al. Dupilumab versus cyclosporine for the treatment of moderate-to-severe atopic dermatitis in adults: indirect comparison using the Eczema Area and severity index. Acta Derm Venereol. 2019;99(10):851–857.
   PubMed Web of Science ®Google Scholar
• Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467–474.
   PubMed Web of Science ®Google Scholar
• Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020;33(5). doi: 10.1111/dth.13687.
   Web of Science ®Google Scholar
• Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271–282.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a Comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443–456.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Yeung J. Patient-Driven discontinuation of dupilumab during the COVID-19 pandemic in two academic hospital clinics at the university of Toronto. J Cutan Med Surg. 2020;24(4):422–423.
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Romagnuolo M, Angileri L, et al. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol. 2020;34:e303–4.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Guttman-Yassky. Two Phase 3 trials of dupilumab versus Placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. .
   PubMed Web of Science ®Google Scholar
• Kearns DG, Uppal S, Vipawee S, et al. Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(3):e251–e252.
   PubMed Web of Science ®Google Scholar
• Carugno A, Raponi F, Locatelli AG, et al. No evidence of increased risk for coronavirus disease 2019 (COVID-19) in patients treated with dupilumab for atopic dermatitis in a high-epidemic area – bergamo, Lombardy, Italy. J Eur Acad Dermatol Venereol. 2020;34:e433–4.
   PubMed Web of Science ®Google Scholar
• Rossi M, Rovati C, Arisi M, et al. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience. Dermatol Ther. 2020;33(4). DOI:10.1111/dth.13765.
   Web of Science ®Google Scholar
• Caroppo F, Biolo G, Belloni Fortina A. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab. J Eur Acad Dermatol Venereol. 2020;34:e368.
   PubMed Web of Science ®Google Scholar
• Ordóñez-Rubiano MF, Campo I, Casas M. Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients. Dermatol Ther. 2020;33(6). DOI:10.1111/dth.14172.
   PubMed Web of Science ®Google Scholar
• Ordóñez-Rubiano MF, Rubiano-Mojica PC, Young CM. HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis. Int J Derm. 2021;2019:2020–2021.
   Google Scholar
• Thangaraju P, Venkatesan N, Sudha TYS, et al. Role of dupilumab in approved indications of COVID-19 patient: an Efficacy-Based nonsystematic critical analysis. SN Compr Clin Med. 2020;2(11):2126–2130.
   PubMedGoogle Scholar
• International League of Dermatological Societoes (ILDS). Guidance on the use of systemic therapy for patients with Psoriasis/Atopic Derma- titis during the COVID-19 (SARS-CoV-2 CP (April 2020). [cited 2020 Nov 10]. Available from: https://ilds.org/covi.-19/guidance-psoriasis-atopic-dermatitis
   Google Scholar
• Law Ping Man S, Bouzillé G, Beneton N, et al. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine. J Eur Acad Dermatol Venereol. 2018;32(8):1327–1335.
   PubMed Web of Science ®Google Scholar
• Taieb Y, Baum S, Ben Amitai D, et al. The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study. J Dermatolog Treat. 2019;30(3):240–244.
   PubMed Web of Science ®Google Scholar
• Dvorakowa V, O’Regan GM, Irvine AD. Methotrexate for severe childhood atopic dermatitis: clinical experience in a tertiary center. Pediatr Dermatol. 2017 Sep;34(5):528–534. . Epub 2017 Jul 21.
   PubMed Web of Science ®Google Scholar
• Deo M, Yung A, Hill S, et al. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol. 2014;53(8):1037–1041.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
   PubMed Web of Science ®Google Scholar
• Dávila-Seijo P, Dauden E, Descalzo MA, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol. 2017;137(2):313–321.
   PubMed Web of Science ®Google Scholar
• Goujon C, Viguier M, Staumont-Sallé D, et al. Methotrexate versus cyclosporine in adults with moderate-to-Severe Atopic dermatitis: a Phase III randomized noninferiority trial. J Allergy Clin Immunol Pract. 2018;6(2):562–569.e3.
   PubMed Web of Science ®Google Scholar
• Klimek L, Pfaar O, Worm M, et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. Allergol Sel. 2020;4(1):53–68.
   PubMedGoogle Scholar
• Schneeweiss MC, Perez-Chada L, Merola JF. Comparative safety of systemic immuno-modulatory medications in adults with atopic dermatitis. J Am Acad Dermatol. 2019. DOI:10.1016/j.jaad.2019.05.073.
   PubMedGoogle Scholar
• Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147(2):324–330.
   PubMed Web of Science ®Google Scholar
• Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68(1):29–35.
   PubMed Web of Science ®Google Scholar
• Drenovska K, Schmidt E, Vassileva S. Covid-19 pandemic and the skin. Int J Dermatol. 2020;1–8. DOI:10.1111/ijd.15189.
   Google Scholar
• Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: an EAACI statement. Allergy. 2020;75(11):2764–2774.
   PubMed Web of Science ®Google Scholar
• Chaudhary NS, Donnelly JP, Moore JX, et al. Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort. Crit Care. 2017;21(1):1–8.
   PubMedGoogle Scholar
• Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long- course oral corticosteroids in children. PLoS One. 2017;12(1):1–18.
   Web of Science ®Google Scholar
• Ni YN, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23(1):1–9.
   PubMedGoogle Scholar
• Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890–897.
   PubMedGoogle Scholar
• Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310–317.e1.
   PubMed Web of Science ®Google Scholar
• Van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, et al. No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Syst Rev. 2014;3(1):1–5.
   PubMedGoogle Scholar
• Brough HA, Kalayci O, Sediva A, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics. Pediatr Allergy Immunol. 2020;31(5):442–448.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Flohr C, Simon D, et al. European task force on atopic dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34:e241–2.
   PubMed Web of Science ®Google Scholar
• Shaker MS, Oppenheimer J, Grayson M, et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol. 2020;8(5):1477–1488. .
   Web of Science ®Google Scholar
• The British Society of Allergy and Clinical Immunlogy. [cited 2020 Nov 10]. Available from: https://www.bsaci.org/announcements/modifications-for-adult-allergy-services-during-covid-19-pandemic
   Google Scholar
• American Academy of Dermatology. Guidance March 20, 2020. [cited 2020 Nov 10]. Available from: www.aad.org
   Google Scholar